Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: Final results of CALGB (Alliance) 10301, a multicentre phase II study

Peter M. Voorhees; Robert Z. Orlowski; Flora Mulkey; Peter Watson; Susan Geyer; Ben L. Sanford; Elizabeth Bennett; Asher A. Chanan-Khan; Clara D. Bloomfield; Richard A. Larson

doi:10.1111/bjh.13592

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: Final results of CALGB (Alliance) 10301, a multicentre phase II study

Peter M. Voorhees, Robert Z. Orlowski, Flora Mulkey, Peter Watson, Susan Geyer, Ben L. Sanford, Elizabeth Bennett, Asher A. Chanan-Khan, Clara D. Bloomfield, Richard A. Larson

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.

Original language	English (US)
Pages (from-to)	373-377
Number of pages	5
Journal	British journal of haematology
Volume	171
Issue number	3
DOIs	https://doi.org/10.1111/bjh.13592
State	Published - Nov 2015

Keywords

Anthracyclines
International staging system
Multiple myeloma
Proteasome inhibitors

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.13592

Cite this

Voorhees, P. M., Orlowski, R. Z., Mulkey, F., Watson, P., Geyer, S., Sanford, B. L., Bennett, E., Chanan-Khan, A. A., Bloomfield, C. D., & Larson, R. A. (2015). Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: Final results of CALGB (Alliance) 10301, a multicentre phase II study. British journal of haematology, 171(3), 373-377. https://doi.org/10.1111/bjh.13592

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: Final results of CALGB (Alliance) 10301, a multicentre phase II study. / Voorhees, Peter M.; Orlowski, Robert Z.; Mulkey, Flora et al.
In: British journal of haematology, Vol. 171, No. 3, 11.2015, p. 373-377.

Research output: Contribution to journal › Article › peer-review

Voorhees, PM, Orlowski, RZ, Mulkey, F, Watson, P, Geyer, S, Sanford, BL, Bennett, E, Chanan-Khan, AA, Bloomfield, CD & Larson, RA 2015, 'Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: Final results of CALGB (Alliance) 10301, a multicentre phase II study', British journal of haematology, vol. 171, no. 3, pp. 373-377. https://doi.org/10.1111/bjh.13592

@article{5a59df072b4e4791b39a58d19d81a45b,

title = "Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: Final results of CALGB (Alliance) 10301, a multicentre phase II study",

abstract = "Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.",

keywords = "Anthracyclines, International staging system, Multiple myeloma, Proteasome inhibitors",

author = "Voorhees, {Peter M.} and Orlowski, {Robert Z.} and Flora Mulkey and Peter Watson and Susan Geyer and Sanford, {Ben L.} and Elizabeth Bennett and Chanan-Khan, {Asher A.} and Bloomfield, {Clara D.} and Larson, {Richard A.}",

note = "Publisher Copyright: {\textcopyright} 2015 John Wiley & Sons Ltd.",

year = "2015",

month = nov,

doi = "10.1111/bjh.13592",

language = "English (US)",

volume = "171",

pages = "373--377",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib

T2 - Final results of CALGB (Alliance) 10301, a multicentre phase II study

AU - Voorhees, Peter M.

AU - Orlowski, Robert Z.

AU - Mulkey, Flora

AU - Watson, Peter

AU - Geyer, Susan

AU - Sanford, Ben L.

AU - Bennett, Elizabeth

AU - Chanan-Khan, Asher A.

AU - Bloomfield, Clara D.

AU - Larson, Richard A.

PY - 2015/11

Y1 - 2015/11

N2 - Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.

AB - Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). Out of 61 patients, the overall response rate was 57% and the near-complete/complete response rate was 7%. Patients aged ≥65 years old had a higher incidence of treatment-related ≥Grade 3 non-haematological toxicity (80% vs. 51%, P = 0·020). Median overall survival was 5·6 years and negatively impacted by the presence of International Staging System stage III disease, underscoring the need for novel treatment strategies for this group of patients.

KW - Anthracyclines

KW - International staging system

KW - Multiple myeloma

KW - Proteasome inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84944277337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944277337&partnerID=8YFLogxK

U2 - 10.1111/bjh.13592

DO - 10.1111/bjh.13592

M3 - Article

C2 - 26202857

AN - SCOPUS:84944277337

SN - 0007-1048

VL - 171

SP - 373

EP - 377

JO - British journal of haematology

JF - British journal of haematology

IS - 3

ER -

Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: Final results of CALGB (Alliance) 10301, a multicentre phase II study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this